What second-line therapy would you recommend for a patient with a pathogenic BRCA-1 mutation and stage IIIA fallopian tube high-grade serous carcinoma, who underwent R0 cytoreduction followed by 6 cycles of carboplatin/paclitaxel with complete response, who has now progressed 13 months into olaparib maintenance?